Elevai Labs, Inc. Common Stock - Asset Resilience Ratio
Elevai Labs, Inc. Common Stock (ELAB) has an Asset Resilience Ratio of 1.78% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Elevai Labs, Inc. Common Stock to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2024–2025)
This chart shows how Elevai Labs, Inc. Common Stock's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Elevai Labs, Inc. Common Stock.
Liquid Assets Composition Over Time
This chart breaks down Elevai Labs, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of Elevai Labs, Inc. Common Stock to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $650.60K | 1.78% |
| Total Liquid Assets | $650.60K | 1.78% |
Asset Resilience Insights
- Limited Liquidity: Elevai Labs, Inc. Common Stock maintains only 1.78% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Elevai Labs, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Elevai Labs, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Elevai Labs, Inc. Common Stock (2024–2025)
The table below shows the annual Asset Resilience Ratio data for Elevai Labs, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.45% | $572.05K | $12.87 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $8.99 Million | -- |
About Elevai Labs, Inc. Common Stock
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing … Read more